KRAS and BRAF gene mutations in correlation with clinicopathologic features of colorectal carcinoma in Chinese

Chinese Journal of Pathology

Volumn 41, Issue 9, 2012, Pages 584-589

  Zhu, Xiao Li ^a   Cai, Xu ^a   Zhang, Ling ^a   Yang, Fei ^a   Sheng, Wei Qi ^a   Lu, Yong Ming ^a   Du, Xiang ^a   Zhou, Xiao Yan ^a  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

Author keywords

Colorectal neoplasms; DNA mutational analysis; Polymerase chain reaction; Sequence analysis

Indexed keywords

B RAF KINASE; BRAF PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN;

ADOLESCENT; ADULT; AGED; ARTICLE; ASCENDING COLON; ASIAN; CODON; COLON TUMOR; COLORECTAL TUMOR; DESCENDING COLON; FEMALE; GENETICS; HUMAN; MALE; MIDDLE AGED; MUTATION; PATHOLOGY; RECTUM TUMOR; SEX DIFFERENCE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; CODON; COLON, ASCENDING; COLON, DESCENDING; COLONIC NEOPLASMS; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; RECTAL NEOPLASMS; SEX FACTORS; YOUNG ADULT;

EID: 84867494944     PISSN: 05295807     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0529-5807.2012.09.003     Document Type: Article

References (24)

1. Nordlinger B, Guiguet M, Vaillant JC, et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer, 1996, 77(7):1254-1262.
2. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med, 2008, 359(17):1757-1765.
3. Amado HC, Wolf M, Peelers M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol, 2008, 26(10):1626-1634.
4. Peelers M, Price TJ, Cervantes A, et al. Randomized phase IE study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRi) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol, 2010, 28(31):47064713.
5. Bokemeyer C, Bondarenko I, Hartmann JT, et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as firstline treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol, 2011, 22(7):1535-1546.
6. NCCN. Clinical practice guidelines in oncology: colon cancer. Version3. 2012 [EB/OL].[2012-07-16]. http://www.nccn. org/professionals/physician-gls/pdf/ colon.pdf.
7. der CJ, Cooper CM. Altered gene products are associated with activation of cellular Kras genes in human lung and colon carcinomas. Cell, 1983, 32(1):201-208.
8. Gideon P, John J, Freeh M, et al. Mutational and kinetic analyses of the GTPase-activating protein (GAP)-p21 interaction: the C-terminal domain of GAP is not sufficient for full activity. Mol Cell Biol, 1992, 12(5):2050-2056.
9. Rajagopalan H, Bardelli A, Lengauer C, et al. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature, 2002, 418(6901):934.
10. Samowitz WS, Curtin K, Schaffer D, et al. Relationship of K-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study. Cancer Epidemiol Biomarkers Prev, 2000, 9(11):1193-1197.
11. Lea IA, Jackson M A, Li X, et al. Genetic pathways and mutation profiles of human cancers: site-and exposure-specific patterns. Carcinogenesis, 2007, 28(9):1851-1858.
12. van Krieken JH, Jung A, Kirchner T, et al. KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma; proposal for an European quality assurance program. Virchows Arch, 2008, 453(5):417431.
13. Neumann J, Zeindl-Eberhart E, Kirchner T, et al. Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. Pathol Res Pract, 2009, 205(12):858-862.
14. Sylvester BE, Huo D, Khramtsov A, et al. Molecular analysis of colorectal tumors within a diverse patient cohort at a single institution. Clin Cancer Kes, 2012, 18(2):350-359.
15. Bazan V, Migliavacca M, Zanna I, et al. Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype. Ann Oncol, 2002, 13(9):1438-1446.
16. Modest DP, Stintzing S, Laubender RP, et al. Clinical characterization of patients with metastatic colorectal cancer depending on the KRAS status. Anticancer Drugs, 2011, 22(9):913-918.
17. De Roock W, Jonker DJ, Di Nicolantonio F, et al. Association of KRAS p. G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA, 2010, 304(16):1812-1820.
18. Yokota T, Ura T, Shibata N, et al. BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. Br J Cancer, 2011, 104(5):856-862.
19. Di Nicolantonio F, Martini M, Molinari F, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol, 2008, 26(35):5705-5712.
20. Prahallad A, Sun C, Huang S, et al. Unresponsiveness of colon cancer to BRAF (Y600E) inhibition through feedback activation of EGFR. Nature, 2012, 483(7387):100-103.
21. Chan TL, Zhao W, Leung SY, et al. BRAF and KRAS mutations in colorectal hyperplastic polyps and serrated adenomas. Cancer Res, 2003, 63(16):48784881.
22. Yuen ST, Davies H, Chan TL, et al. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res, 2002, 62(22):6451-6455.
23. Roth AD, Tejpar S, Delorenzi M, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer; results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol, 2010, 28(3):466474.
24. Liou JM, Wu MS, Shun CT. et al. Mutations in BRAF correlate with poor survival of colorectal cancers in Chinese population. Int J Colorectal Dis, 2011, 26(11):1387-1395.